MICHAEL GENTILE: Open Payments
NPI 1649386020 · RIDGEWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,045 in 60 payments from 7 companies in 2025. Trend: 2023 $516 · 2024 $773 · 2025 $1,045
Food & beverage: $1,045
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 15 | $288 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $178 |
| ABBVIE INC. | 12 | $159 |
| Vanda Pharmaceuticals Inc. | 6 | $100 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Lundbeck LLC | 1 | $16 |
Products named: Auvelity, CAPLYTA, TRINTELLIX, VRAYLAR, REXULTI, FANAPT, HETLIOZ.
Industry payments across NJ — which companies pay providers there.
